Keyword: Descovy

At the current rate, Gilead could switch about 50% to 60% of PrEP users off Truvada by the time Teva launches its 2020 copycat, analysts predict.

Gilead Sciences balked at licensing the U.S. government's HIV-prevention patent rights, and now the feds are striking back.

Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light. New safety data over a competitor could help its case.

If Gilead’s investors are worried the company’s new leadership team won’t pony up to support key launches, they don’t need to be, its CEO says.

Gilead Sciences scored a major win with a pre-exposure nod for next-gen HIV/AIDS med Descovy. Now a consumer group wants the price significantly cut.

The lack of warnings for bone mineral density loss could be a key selling point for Gilead to drive switching from Truvada to Descovy, analysts say.

Gilead’s Descovy secured backing from an FDA panel for HIV prevention in men and transgender women. But beyond that, it ran into issues.

As FDA panel experts gear up to debate the merits of Gilead’s Descovy for PrEP, the question isn't whether it’s worthy of an indication in men.